AR055346A1 - Composiciones farmaceuticas de glp -1 - Google Patents
Composiciones farmaceuticas de glp -1Info
- Publication number
- AR055346A1 AR055346A1 ARP060102840A ARP060102840A AR055346A1 AR 055346 A1 AR055346 A1 AR 055346A1 AR P060102840 A ARP060102840 A AR P060102840A AR P060102840 A ARP060102840 A AR P060102840A AR 055346 A1 AR055346 A1 AR 055346A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- formula
- analogs
- glp
- cells
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 101710173663 Glucagon-1 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000297 inotrophic effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000035764 nutrition Effects 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Análogos peptídicos de péptido-1 tipo glucagon, sus sales farmacéuticamente aceptables, a método para la utilizacion de tales análogos para tratar mamíferos y a composiciones farmacéuticas utiles para tal fin que comprenden dichos análogos. Reivindicacion 1: Una composicion farmacéutica que comprende un análogo de acuerdo con la formula: [Aib8,35]hGLP-1(7-36)NH2; junto con zinc y un portador o diluyente farmacéuticamente aceptable. Reivindicacion 37: Un método para activar un efecto agonista de GLP-1, comprendiendo dicho método poner en contacto un receptor del ligando GLP-1(7-36)NH2 con el compuesto de acuerdo con la formula (1), dicho compuesto de acuerdo con la formula (1) es proporcionado a dicho receptor, directa a indirectamente, por medio de una composicion de acuerdo con la reivindicacion 1. Reivindicacion 44: Un método para convertir células madre/progenitoras hepáticas en células pancreáticas funcionales, para prevenir el deterioro de células beta y para estimular la proliferacion de células beta, para suprimir los niveles sanguíneos plasmáticos de norepinefrina, para inducir una respuesta inotropica y para aumentar la contractilidad cardíaca, para mejorar la nutricion por medio de una ruta no alimentaría, para el pretratamiento de un sujeto para sufrir un procedimiento endoscopico, y para modular los niveles de triglicéridos, en un sujeto que lo necesita, comprendiendo dicho método administrar a dicho sujeto una composicion farmacéutica de acuerdo con la reivindicacion 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69614205P | 2005-06-30 | 2005-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055346A1 true AR055346A1 (es) | 2007-08-22 |
Family
ID=37605098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102840A AR055346A1 (es) | 2005-06-30 | 2006-06-30 | Composiciones farmaceuticas de glp -1 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8236759B2 (es) |
| EP (2) | EP1904525A4 (es) |
| KR (1) | KR20080028981A (es) |
| CN (1) | CN101258163B (es) |
| AR (1) | AR055346A1 (es) |
| AU (1) | AU2006265814B2 (es) |
| CA (1) | CA2617859A1 (es) |
| EA (1) | EA012287B1 (es) |
| MX (1) | MX2008001468A (es) |
| NO (1) | NO20080552L (es) |
| NZ (1) | NZ565535A (es) |
| TW (1) | TWI364292B (es) |
| WO (1) | WO2007005738A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008082656A1 (en) * | 2006-12-29 | 2008-07-10 | Ipsen Pharma S.A.S. | Glp-1 pharmaceutical compositions |
| CN101678019B (zh) * | 2007-06-08 | 2016-03-30 | 詹森药业有限公司 | 哌啶/哌嗪衍生物 |
| JP5443342B2 (ja) * | 2007-06-08 | 2014-03-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ピペリジン／ピペラジン誘導体 |
| ES2483898T3 (es) * | 2007-06-08 | 2014-08-08 | Janssen Pharmaceutica, N.V. | Derivados de piperidina/piperazina |
| JO2972B1 (en) * | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| WO2009147170A2 (en) | 2008-06-05 | 2009-12-10 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
| EP2216042A1 (en) * | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
| TWI668010B (zh) * | 2014-05-07 | 2019-08-11 | 丹麥商諾佛 儂迪克股份有限公司 | 使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4591496A (en) * | 1984-01-16 | 1986-05-27 | Massachusetts Institute Of Technology | Process for making systems for the controlled release of macromolecules |
| US4810501A (en) * | 1986-06-17 | 1989-03-07 | Warner-Lambert Company | Sustained release pharmaceutical preparations |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5271945A (en) * | 1988-07-05 | 1993-12-21 | Takeda Chemical Industries, Ltd. | Sustained release microcapsule for water soluble drug |
| JP3277342B2 (ja) * | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| TW333456B (en) * | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| HU225496B1 (en) | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
| US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
| US5614487A (en) * | 1993-05-28 | 1997-03-25 | Genentech, Inc. | Sustained release pharmaceutical composition |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| CA2137206A1 (en) | 1993-12-09 | 1995-06-10 | John A. Galloway | Glucagon-like insulinotropic peptides, compositions and methods |
| EP0668073B1 (en) * | 1994-02-21 | 1999-04-14 | Takeda Chemical Industries, Ltd. | Polyester matrix for a pharmaceutical sustained-release preparation |
| US20010006943A1 (en) | 1994-12-23 | 2001-07-05 | Ejvind Jensen | Protracted GLP-1 compositions |
| US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| DE69737916T2 (de) | 1996-11-12 | 2008-04-03 | Novo Nordisk A/S | Verwendung von GLP-1 Peptiden |
| US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
| AU2610599A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
| KR20010042079A (ko) | 1998-03-20 | 2001-05-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 생리학적으로 활성인 폴리펩티드의 서방 제제 및 그것의제조 방법 |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| RU2205188C2 (ru) | 1998-06-30 | 2003-05-27 | Ново Нордиск А/С | Затравочные кристаллы для получения пептидов или протеинов |
| EP1306091A3 (en) | 1998-07-31 | 2003-05-21 | Novo Nordisk A/S | Stimulation of beta cell proliferation |
| MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
| US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| CZ295889B6 (cs) | 1998-12-07 | 2005-11-16 | Societe De Conseils De Recherches Et D'application | Analogy GLP-1, mající arginin na pozicích 26 a 34, jejich použití a farmaceutické prostředky je obsahující |
| JP4548623B2 (ja) * | 1999-02-24 | 2010-09-22 | 多木化学株式会社 | 生体材料 |
| US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| AU5760900A (en) | 1999-06-25 | 2001-01-31 | Minimed, Inc. | Multiple agent diabetes therapy |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US6569832B1 (en) | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| DK1246638T4 (da) | 2000-01-10 | 2014-09-22 | Amylin Pharmaceuticals Llc | Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi |
| US6844321B2 (en) | 2000-01-31 | 2005-01-18 | Novo Nordisk A/S | Crystallization of a GLP-1 analogue |
| WO2001057084A1 (en) | 2000-01-31 | 2001-08-09 | Novo Nordisk A/S | Crystallisation of a glp-1 analogue |
| KR20030009389A (ko) | 2000-03-14 | 2003-01-29 | 브루카드 괴케 | 유문동-유문-십이지장 운동성에 대한 글루카곤 유사펩티드-1 (7-36)의 효과 |
| CA2407784C (en) | 2000-05-19 | 2014-08-26 | Bionebraska, Inc. | Treatment of acute coronary syndrome with glp-1 |
| ATE346093T1 (de) * | 2000-06-16 | 2006-12-15 | Lilly Co Eli | Analoge des glucagon ähnlichen peptid-1 |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| WO2002016430A2 (en) | 2000-08-24 | 2002-02-28 | Thomas Jefferson University | Peptide with effects on cerebral health |
| US6894024B2 (en) | 2000-10-20 | 2005-05-17 | Amylin Pharmaceuticals, Inc. | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide |
| AU2002239384B2 (en) | 2000-12-13 | 2007-01-11 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| EP1351984A2 (en) | 2000-12-13 | 2003-10-15 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| BR0212620A (pt) | 2001-10-01 | 2005-09-20 | Lilly Co Eli | Métodos de tratamento de pacientes criticamente doentes sofrendo de angústia respiratória, e de pacientes criticamente doente possuindo uma condição que acarreta a angústia respiratória, e, uso de um composto de glp-1 |
| US20050053588A1 (en) | 2001-10-18 | 2005-03-10 | Li Yin | Conversion of liver stem and progenitor cells to pancreatic functional cells |
| JP2005508360A (ja) | 2001-10-19 | 2005-03-31 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１およびインスリンの二相混合物 |
| AU2002351752A1 (en) | 2001-12-29 | 2003-07-30 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| US7105489B2 (en) | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| US20030199445A1 (en) | 2002-02-07 | 2003-10-23 | Knudsen Lotte Bjerre | Use of GLP-1 compound for treatment of critically ill patients |
| US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| US20040209803A1 (en) | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
| CA2550695A1 (en) | 2003-12-16 | 2005-06-30 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Glp-1 pharmaceutical compositions |
| ES2375802T3 (es) * | 2004-04-15 | 2012-03-06 | Alkermes Pharma Ireland Limited | Dispositivo de liberación sostenida a base de pol�?mero. |
| US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
| EP1750683B1 (en) * | 2004-04-23 | 2013-01-09 | Amgen Inc. | Sustained release formulations |
| WO2005112949A1 (en) * | 2004-05-20 | 2005-12-01 | Diamedica Inc. | Use of drug combinations for treating insulin resistance |
-
2006
- 2006-06-30 US US11/479,074 patent/US8236759B2/en not_active Expired - Fee Related
- 2006-06-30 MX MX2008001468A patent/MX2008001468A/es unknown
- 2006-06-30 TW TW095124004A patent/TWI364292B/zh not_active IP Right Cessation
- 2006-06-30 AU AU2006265814A patent/AU2006265814B2/en not_active Ceased
- 2006-06-30 WO PCT/US2006/025826 patent/WO2007005738A2/en not_active Ceased
- 2006-06-30 NZ NZ565535A patent/NZ565535A/en not_active IP Right Cessation
- 2006-06-30 AR ARP060102840A patent/AR055346A1/es not_active Application Discontinuation
- 2006-06-30 KR KR1020087002509A patent/KR20080028981A/ko not_active Ceased
- 2006-06-30 CN CN200680031646XA patent/CN101258163B/zh not_active Expired - Fee Related
- 2006-06-30 CA CA002617859A patent/CA2617859A1/en not_active Abandoned
- 2006-06-30 EA EA200800181A patent/EA012287B1/ru not_active IP Right Cessation
- 2006-06-30 EP EP06774416A patent/EP1904525A4/en not_active Withdrawn
- 2006-06-30 EP EP12150837A patent/EP2441460A1/en not_active Withdrawn
-
2008
- 2008-01-30 NO NO20080552A patent/NO20080552L/no not_active Application Discontinuation
-
2012
- 2012-07-09 US US13/544,035 patent/US20120277151A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2441460A1 (en) | 2012-04-18 |
| NZ565535A (en) | 2011-03-31 |
| KR20080028981A (ko) | 2008-04-02 |
| WO2007005738A2 (en) | 2007-01-11 |
| AU2006265814A1 (en) | 2007-01-11 |
| MX2008001468A (es) | 2008-04-07 |
| US8236759B2 (en) | 2012-08-07 |
| CA2617859A1 (en) | 2007-01-11 |
| EA012287B1 (ru) | 2009-08-28 |
| TWI364292B (en) | 2012-05-21 |
| US20120277151A1 (en) | 2012-11-01 |
| WO2007005738A3 (en) | 2007-09-13 |
| AU2006265814B2 (en) | 2012-05-10 |
| CN101258163A (zh) | 2008-09-03 |
| EP1904525A2 (en) | 2008-04-02 |
| EA200800181A1 (ru) | 2008-06-30 |
| EP1904525A4 (en) | 2009-10-21 |
| NO20080552L (no) | 2008-03-27 |
| TW200740456A (en) | 2007-11-01 |
| CN101258163B (zh) | 2013-08-21 |
| US20070021339A1 (en) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
| MX2019006260A (es) | Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad. | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| CR10288A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
| PE20160683A1 (es) | Analogos de glucagon acilados | |
| CO2017006737A2 (es) | Análogos de gip y glp-1 en donde la lisina (k) en la posición 20 está químicamente modificada a través de la conjugación al grupo épsilon-amino de la cadena lateral k con ([2-(2-amino-etoxi)-etoxi]-acetil)2-(γglu)a-co-(ch2)b-co2h activos como agonistas de receptores gip y gip-1 | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| DOP2012000244A (es) | Nuevos péptidos y métodos para su preparación y uso | |
| ECSP12011593A (es) | Análogos de glucagón acilados | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
| ATE457979T1 (de) | Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate | |
| SV2009003146A (es) | Moduladores del metabolismo y tratamiento de los transtornos metabolicos ref. 20750-0033sv1 (137. sv1.pct) | |
| AR085086A1 (es) | Uso de analogos de glucagon acilados | |
| CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
| AR055346A1 (es) | Composiciones farmaceuticas de glp -1 | |
| CR20120062A (es) | Terapia combinada para el tratamiento de la diabetes | |
| PE20190515A1 (es) | Peptidos modificados de auristatina y conjugados anticuerpo-farmaco de los mismos | |
| CY1108690T1 (el) | Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων | |
| AR111199A1 (es) | Compuesto aromático agonista de gpr40 | |
| CU20120002A7 (es) | DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA | |
| PE20200606A1 (es) | Composiciones solidas para administracion oral | |
| PE20070022A1 (es) | Compuestos derivados de pirrolopiridina como inhibidores de dipeptidil peptidasa iv | |
| CL2008003927A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina-2-heterociclil-metanona, moduladores de los receptores nucleares nurr1; compuestos intermediarios; composicion farmaceutica; medicamento; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, psiquiatricas, inflamatorias, osteoporosis, cancer, entre otras. | |
| AR072425A1 (es) | Uso de nifurtimox para el tratamiento de giardiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |